Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Lagerström-Fermér

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Genomics|March 20, 2002
Comparative genomics by capture PCRMaria Lagerström-Fermér, Dan Larhammar, Elsy Johnsen, et al.
Genomics|April 12, 2002
Increased gene dosage at Xq26-q27 is associated with X-linked hypopituitarismNicola M Solomon, Sara Nouri, Garry L Warne, et al.
Clinical Pharmacology in Drug Development|December 4, 2019
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral BioavailabilityHans Ericsson, Karin Nelander, Maria Heijer, et al.
Molecular Therapy. Methods & Clinical Development|July 31, 2020
Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical TrialVesa Anttila, Antti Saraste, Juhani Knuuti, et al.
British Journal of Clinical Pharmacology|January 9, 2019
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteersLi-Ming Gan, Maria Lagerström-Fermér, Hans Ericsson, et al.
Biochemical Pharmacology|July 8, 2008
Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variantsIngela Ahlstedt, Susanna Engberg, John Smith, et al.
Breast Cancer Research : BCR|June 26, 2004
Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control studySara Wedrén, Lovisa Lovmar, Keith Humphreys, et al.
BMC Cancer|November 8, 2008
Estrogen receptor alpha gene polymorphism and endometrial cancer risk--a case-control studySara Wedrén, Lovisa Lovmar, Keith Humphreys, et al.
Contemporary Clinical Trials Communications|September 3, 2020
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarctionEva Prescott, John Pernow, Antti Saraste, et al.
Vascular Health and Risk Management|November 8, 2019
PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserveInger Haraldsson, Li-Ming Gan, Sara Svedlund, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Genomics|March 20, 2002
Comparative genomics by capture PCRMaria Lagerström-Fermér, Dan Larhammar, Elsy Johnsen, et al.
Genomics|April 12, 2002
Increased gene dosage at Xq26-q27 is associated with X-linked hypopituitarismNicola M Solomon, Sara Nouri, Garry L Warne, et al.
Clinical Pharmacology in Drug Development|December 4, 2019
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral BioavailabilityHans Ericsson, Karin Nelander, Maria Heijer, et al.
Molecular Therapy. Methods & Clinical Development|July 31, 2020
Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical TrialVesa Anttila, Antti Saraste, Juhani Knuuti, et al.
British Journal of Clinical Pharmacology|January 9, 2019
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteersLi-Ming Gan, Maria Lagerström-Fermér, Hans Ericsson, et al.
Biochemical Pharmacology|July 8, 2008
Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variantsIngela Ahlstedt, Susanna Engberg, John Smith, et al.
Breast Cancer Research : BCR|June 26, 2004
Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control studySara Wedrén, Lovisa Lovmar, Keith Humphreys, et al.
BMC Cancer|November 8, 2008
Estrogen receptor alpha gene polymorphism and endometrial cancer risk--a case-control studySara Wedrén, Lovisa Lovmar, Keith Humphreys, et al.
Contemporary Clinical Trials Communications|September 3, 2020
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarctionEva Prescott, John Pernow, Antti Saraste, et al.
Vascular Health and Risk Management|November 8, 2019
PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserveInger Haraldsson, Li-Ming Gan, Sara Svedlund, et al.
Pageof 2